Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Kovner Bruce purchased 1,250,000 shares of the stock in a transaction that occurred on Friday, April 11th. The shares were purchased at an average cost of $4.01 per share, with a total value of $5,012,500.00. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock performance was 1.01% in last session and finished the day at $4.01. Traded volume was 1.90million shares in the last session and the average volume of the stock remained 2.58million shares. The beta of the stock remained 2.93. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) insider ownership is 6.00%.
Repligen Corporation (NASDAQ:RGEN)’s share were purchased by Jefferies Group with target price of $17.00 that occurred on Tuesday, April 15th. Repligen Corporation (NASDAQ:RGEN) dropped -1.14 percent to $15.66 Monday on volume of 900,669.00million shares. The intra-day range of the stock was $15.47 to $15.84. Repligen Corporation (NASDAQ:RGEN) has a market capitalization of $501.74million.
Equinix Inc (NASDAQ:EQIX) major shareholder Advisory Corp Spo purchased 71,900 shares of the company’s stock on the open market in a transaction dated Wednesday, April 16th. The stock was purchased at an average cost of $171.70 per share, with a total value of $12,345,230.00. Equinix Inc (NASDAQ:EQIX)’s stock on Apr 21, 2014 reported a increase of 0.75% to the closing price of $180.31. Its fifty two weeks range is $152.82 -$231.56. The total market capitalization recorded $8.91billion. The overall volume in the last trading session was 651,548.00million shares. In its share capital, EQIX has million outstanding shares.
AspenBio Pharma (NASDAQ:APPY) SVP Donald R. Hurd purchased 35,000 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were purchased at an average cost of $2.04 per share, with a total value of $71,400.00. AspenBio Pharma (NASDAQ:APPY) SVP Donald R. Hurd purchased 35,000 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were purchased at an average cost of $2.04 per share, with a total value of $71,400.00. On Monday, shares of AspenBio Pharma (NASDAQ:APPY) dropped -2.24% to close the day at $2.18. Company monthly performance is recorded as -25.60%. AspenBio Pharma (NASDAQ:APPY) quarterly revenue growth is -20.44%.
Discover more from Tech News
Subscribe to get the latest posts sent to your email.
